Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus

AIDS Patient Care and STDs

Volumn 20, Issue 10, 2006, Pages 678-692

  Lai, Andrew R ^a   Tashima, Karen T ^a,b   Taylor, Lynn E ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ALANINE AMINOTRANSFERASE; AMPRENAVIR PHOSPHATE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; INTERFERON; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALGORITHM; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HEPATITIS; HEPATITIS C; HEPATOMEGALY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; MITOCHONDRIAL TOXICITY; PANCREATITIS; PRACTICE GUIDELINE; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STEATOSIS; VIRUS LOAD; WEIGHT REDUCTION;

ANTI-HIV AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33846440589     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.678     Document Type: Review

References (109)

1. Rauch A, Rickenbach M, Weber R, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402.
2. Strasfeld L, Lo Y, Netski D, Thomas D, Klein R. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003;33:356-364.
3. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33:240-247.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
5. Palella FJ, Delaney KM, Morman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
6. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection: Consensus Panel Recommendations. AIDS 2004;18:1-12.
7. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004;292:2839-2848.
8. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
10. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
11. Bonacini M. Liver injury during highly active antiretroviral therapy: The effect of hepatitis C coinfection. Clin Infect Dis 2004;38(Suppl 2):S104-S108.
12. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
13. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005;40:588-593.
14. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease? AIDS 1998;12:2289-2293.
15. Laguno M, Milinkovic A, de Lazzari E, et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther 2005;10:423-429.
16. Moreno A, Quereda C, Moreno L, et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir Ther 2004;9:133-138.
17. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 2003;13:344-348.
18. Falusi OM, Pulvirenti J, Sarazine J, et al. HIV-infected inpatients in the HAART era: How do hepatitis C virus coinfected patients differ? AIDS Patient Care STDs 2003;17:13-16.
19. Fishbein DA, Lo Y, Reinus JF, et al. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr 2004;37:1367-1375.
20. Macias J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: Harmful impact of nevirapine. AIDS 2004;18:767-774.
21. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44f:47-55.
22. Benhamou Y, DiMartino V, Bochet M, et al. Factors affecting liver fibrosis in HIV and hepatitis C virus coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001;34:283.
23. Brau N, Rodriguez-Torres M, Salvatore M, et al. Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV/HCV-coinfection and makes it the same as in HCV-monoinfection. The Puerto Rico-New York Hepatitis C Study Group. J Hepatology 2004;40(Suppl 1):33.
24. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2004;362:1708-1713.
25. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS 2004;18:2039-2045.
26. Marine-Barjoan E, Saint-Paul MC, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004;18:2163-2170.
27. Braitstein P, Palepu A, Dieterich D, et al. Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. AIDS 2004;18:2221-2234.
28. Datta D, Moyle G, Mandalia S, Gazzard B. Matched case-control study to evaluate risk factors for hyperlactatemia in HIV patients on antiretroviral therapy. HIV Med 2003;4:311-314.
29. McComsey G, Lonergan JT. Mitochondrial dysfunction: Patient monitoring and toxicity management. J Acquir Immune Defic Syndr 2004;37:S30-S35.
30. Johnson AA, Ray AS, Hanes JW, et al. Toxicity of nucleoside analogues and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-4057.
31. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19:585-592.
32. Bäuerle J, Miquel R, Laguno M, et al. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection. AIDS 2005;19:1441-1442.
33. Rivas P, Polo J, de Gorgolas M, Fernandez-Guerrero M. Drug points: Fatal lactic acidosis associated with tenofovir. BMJ 2003;327:711.
34. Murphy M, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003;36:1082-1085.
35. Palmon R, Koo B, Shoultz D, Dieterich D. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2002;29:340-345.
36. Stern JO, Robinson PA, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34(Suppl 1):S21-33.
37. Dieterich D, Robinson P, Love J, Stern J. Drug-induced liver injury associated with the use of non-nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004;38(Suppl 2):S80-S89.
38. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine and efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-189.
39. Viramune (nevirapine). Prescribing information (USA). Ridgefield, CT: Boehringer Ingelheim, 2005.
40. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-120.
41. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatitis with hepatic dysfunction. Clin Infect Dis 2005;40:174-181.
42. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004;35:492-502.
43. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-120.
44. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 2004;292:251-265.
45. st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina: July 8-11, 2001.
46. Martinez-Sierra C, Arizcorreta A, Diaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003;36:491-498.
47. Martin-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study. Clin Infect Dis 2004;38:128-133.
48. Sulkowski, M. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004;38(Suppl 2): S90-S97.
49. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-549.
50. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois: September 14-17, 2003.
51. Johanson FD, Balliram DB. Successful treatment of hepatitis C in a patient with advanced AIDS and decompensated cirrhosis. AIDS Read 2003;13:494-496.
52. Sherman KE, Shire NJ, Cernohous P, et al. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: Lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005;41:1186-1195.
53. Gonzalez-Requena D, Nunez M, Jimenez-Nacher I, et al. Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Hum Retroviruses 2004;20:698-700.
54. Bonfanti P, Ricci E, Penco G, et al. Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir. AIDS 2005;19:1433-1434.
55. Kaletra (lopinavir/ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories, 2005.
56. Dominguez S, Peytavin G, Guiguet M, et al. The HEPADOSE study: evaluation of protease inhibitors and non nucleoside analogue plasma concentrations in HIV/HCV and HIV infected patients [abstract WePp0305]. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, Brazil: July 24-27, 2005.
57. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis 2001;33:1931-1937.
58. French AL, Benning L, Anastos K, et al. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection. Clin Infect Dis 2004;39:402-410.
59. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-1592.
60. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002;346:2039-2046.
61. Young B, Fischl MA, Wilson HM, et al. Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. J Acquir Immune Defic Syndr 2002;31:478-482.
62. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-1263.
63. Vora S, Michon C, Junet C, et al. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy coinfected with hepatitis C is not associated with alteration of liver function tests. AIDS 2000;14:2795-2797.
64. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004;18:2277-2284.
65. Aptivus (tipranavir). Prescribing information (USA). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 2005.
66. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.: October 31-November 2, 2004.
67. th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland: November 14-18, 2004.
68. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973;60:646-649.
69. Hivid (zalcitabine). Prescribing information (USA). Nutley, NJ: Roche Laboratories, 2002.
70. Ziagen (abacavir sulfate). Prescribing information (USA). Research Triangle Park, NC: GlaxoSmithKline, 2002.
71. Kearney PB, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004;43:595-612.
72. Viread (tenofovir disoproxil fumarate). Prescribing information (USA). Foster City, CA: Gilead Sciences, 2003.
73. Dailly E, Billaud E, Reliquet V, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HlV-1-infected patients naïve of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol 2004;60:343-348.
74. Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004;20:716-722.
75. th Pharmacology Workshop. Rome, Italy: April 1-3, 2004.
76. Spengler U, Lichterfeld M, Rockstroh JK. Antiretroviral drug toxicity-A challenge for the hepatologist? J Hepatol 2002;36:283-2894.
77. Reijers MH, Weigel HM, Hart AA, et al. Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000;14:59-67.
78. Norvir (ritonavir). Prescribing information (USA). North Chicago, IL: Abbott Laboratories, 2003.
79. Reyataz (atazanavir sulfate). Prescribing information (USA). Princeton, NJ: Bristol Myers-Squibb, 2004.
80. Lexiva (fosamprenavir calcium). Prescribing information (USA). Research Triangle Park, NC: GlaxoSmithKline, 2005.
81. Crixivan (indinavir sulfate). Prescribing information (USA). Whitehouse Station, NJ: Merck & Co., 2005.
82. Invirase (saquinavir mesylate). Prescribing information (USA). Nutley, NJ: Roche Laboratories, 2004.
83. Sulkowski MS, Felizarta F, Smith C, et al. Daily versus thrice-weekly interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: A multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004;35: 464-472.
84. Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology 2004;39:989-998.
85. Balzarini J, Lee C, Herdewijn P, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 29,39-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991;266:21509-21514.
86. Videx (didanosine). Prescribing information (USA). Princeton, NJ: Bristol-Myers Squibb, 2003.
87. Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-846.
88. Bani-Sadr F, Carrat F, Pol S, Hor R, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/Hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005;40:47-52.
89. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-25.
90. Garcia-Benayas T, Blanco F, Soriano V. Weight loss in HIV infected patients. N Engl J Med 2002;347:1287-1288.
91. Harrison SA, Brunt EM, Qazi RA, et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005;3:604-609.
92. Sim SM, Hoggard PG, Sales SD, et al. Effect of ribavirin on zidodvudine efficacy and toxicity in vitro: A concentration-dependent interaction. AIDS Res Hum Retroviruses 1998;14:1661-1667.
93. Retrovir (zidovudine). Prescribing information (USA). Research Triangle Park, NC: GlaxoSmithKline, 2005.
94. Fuster D, Huertas JA, Gomez G, et al. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Antivir Ther 2005;10:841-847.
95. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280-281.
96. Volberding PA, Levine AM, Dieterich D, et al. Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clin Infect Dis 2004;15:1454-1463.
97. Rendon AL, Nunez M, Romero M, et al. Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients. J Acquir Immune Defic Syndr. 2005;39:401-405.
98. Lonergan J, Barber E, Mathews W. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis. AIDS 2003;17:2495-2499.
99. Montaner J, Cote H, Harris M, et al. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004;38(Suppl 2):S73-S79.
100. Lonergan JT, McComsey GA, Fisher RL, et al. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2004;36:935-942.
101. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
102. Antonucci G, Girardi E, Cozzi-Lepri A, et al. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals. Clin Infect Dis 2005;40: e101-109.
103. Uberti-Foppa C, De Bona A, Morsica G, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:146-152.
104. McGovern B, Bradley M, Galvin S, Bica I. Treatment of HCV facilitates treatment of HIV [Abstract 862]. In: 42nd Infectious Diseases Society of America. Boston, MA: September 30-October 3, 2004.
105. Soto B, Sanchez-Quijano A, Rodrigo L, et al. HIV infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
106. Pegasys (peginterferon alfa-2a). Prescribing information (USA). Nutley, NJ: Hoffmann-La Roche Inc, 2004.
107. Chung RT, Andersen J, Volberding P. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients [letter]. N Engl J Med 2005;351:2342.
108. Torriani FJ, Dieterich DT. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients [letter]. N Engl J Med 2005;351:2341-2342.
109. United States Department of Health and Human Services. Guidelines for the use of HIV of antiretroviral agents in HIV-1-infected adults and adolescents. October 6, 2005. Available at: www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (Last accessed December 5, 2005).